Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $215.84, for a total transaction of $1,295,040.00. Following the completion of the sale, the director directly owned 339,875 shares in the company, valued at approximately $73,358,620. The trade was a 1.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jazz Pharmaceuticals Price Performance
Shares of JAZZ opened at $234.66 on Thursday. The business’s 50-day moving average is $230.15 and its two-hundred day moving average is $217.11. The company has a market capitalization of $15.06 billion, a P/E ratio of 79.82, a P/E/G ratio of 0.46 and a beta of 0.38. Jazz Pharmaceuticals PLC has a fifty-two week low of $128.80 and a fifty-two week high of $266.38. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.58 and a current ratio of 1.82.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.03) by $0.15. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $1.21 billion. During the same quarter in the previous year, the firm posted $8.13 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis. Research analysts predict that Jazz Pharmaceuticals PLC will post 10.84 earnings per share for the current year.
More Jazz Pharmaceuticals News
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat Q3 revenue and earnings expectations, with growth in oncology and rare sleep products cited as drivers. The company raised its 2026 revenue outlook to roughly $4.78 billion–$4.85 billion, above the prior consensus near $4.7 billion. Q3 earnings and outlook
- Positive Sentiment: The company announced a $500 million share buyback, which may support shareholder returns and provide demand for the stock. Share buyback announcement
- Positive Sentiment: Several analysts raised their price targets and maintained bullish ratings after the results, including JPMorgan, Morgan Stanley, RBC and Barclays. Analyst insights
- Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares under a pre-arranged Rule 10b5-1 plan, reducing his position by 1.73%; he retained 339,875 shares after the sale. SEC filing
- Negative Sentiment: Some coverage cautioned that slowing growth and an Actiq-related charge could temper the positive effect of the earnings beat and improved guidance. Earnings outlook risks
Analysts Set New Price Targets
JAZZ has been the subject of a number of analyst reports. Weiss Ratings downgraded Jazz Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, October 28th. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Truist Financial lifted their target price on shares of Jazz Pharmaceuticals from $281.00 to $286.00 and gave the company a “buy” rating in a report on Wednesday, October 7th. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a report on Tuesday, August 4th. Finally, Piper Sandler boosted their target price on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $293.45.
Check Out Our Latest Report on JAZZ
Hedge Funds Weigh In On Jazz Pharmaceuticals
Institutional investors and hedge funds have recently modified their holdings of the business. Bank of New York Mellon Corp increased its stake in Jazz Pharmaceuticals by 44.5% during the 1st quarter. Bank of New York Mellon Corp now owns 1,679,371 shares of the specialty pharmaceutical company’s stock worth $317,485,000 after buying an additional 517,514 shares in the last quarter. Tri Locum Partners LP acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at approximately $29,995,000. Bank of America Corp DE lifted its position in shares of Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after acquiring an additional 99,656 shares in the last quarter. Amundi lifted its position in shares of Jazz Pharmaceuticals by 2,445.3% in the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock valued at $10,519,000 after acquiring an additional 53,454 shares in the last quarter. Finally, Rokos Capital Management LLP purchased a new position in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $9,833,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
